MindMed Results Presentation Deck
May 2022, 40 slides
  1. MindMed
  2. Related Decks
  3. Results Presentation Decks
use disorder potential for unmet treatment needs may am | MindMed
disclaimer | MindMed
agenda a | MindMed
business highlights our mission is to deliver on the therapeutic potential of and other targets to treat brain health disorders leader in developing product candidates to treat brain health disorders diversified pipeline of clinical programs targeting significant unmet medical needs and strategies to maximize market exclusivity and protection leveraging decades of research on clinical and preclinical potential of product candidates industry leading in drug and digital medicine development and commercialization fully funded through key clinical and into | MindMed
advancing multiple generations of drug candidates | MindMed
research development pipeline | MindMed
upcoming portfolio milestones | MindMed
past president of the society of addiction medicine and past chair of the ama council of science and public health | MindMed
kelly associate professor in the behavioral pharmacology research unit within the department of psychiatry and behavioral sciences in the university school of medicine | MindMed
disclosures past years | MindMed
waves of the crisis a | MindMed
withdrawal syndrome craving sleep impairment mood disruption anxiety pression pupil dilation rhinorrhea muscle pain joint aches a diarrhea yawning acute protracted i short hours days days weeks | MindMed
current treatment options treatment type medications for maintenance supervised withdrawal detoxification methadone mor | MindMed
significant agonist treatment gap past year a total moud capacity total capacity a in total methadone capacity year of states had rates of that exceeded capacity in of states the majority of maintenance clinics were at mor | MindMed
supervised withdrawal treatment benefits available patient preference agonists were planned continuum of care poor management overdose no standardization maintenance oes a car most programs do not offer medications mor | MindMed
non treatment options used internationally efficacy supported by retrospective chart reviews case studies and survey studies no available generally administered as a bolus dose for supervised withdrawal narrow therapeutic window elevated cardiac risk | MindMed
synthetic alkaloid congener derived from different mechanism of action antagonist on alpha beta nicotinic receptor better safety profile | MindMed
reduces morphine self administration shifts the dose response curve for self administration down decreasing its efficacy not potency relative to and control tec mor | MindMed
maintains activity on natural reinforcers in contrast to does not reduce responding for a reinforcer suggesting specificity of effects be mor morphine water | MindMed
reduces release des decreases and morphine exposure extracellular in the sensitization following chronic | MindMed
reduces withdrawal severity of some symptoms not direct overlap with in | MindMed
reduces withdrawal severity reductions likely driven by locus locus i i vehicle i i i i i i i a a i shakes i i chattering i i i mor | MindMed
summary primary mechanism less specific low affinity sigma antagonist more specific low affinity for alpha beta nicotinic receptors reinforcement decreased morphine self administration decreased morphine self administration natural reinforcers withdrawal severity decreased responding for water mor decreases likely driven by activity bradycardia hallucinations tremors none on none noted in locus adverse effects | MindMed
so why now alpha adrenergic agonist approved by in for indication of mitigation of withdrawal symptoms not intended as treatment created a new approval pathway and indication recognized to eliminate | MindMed
a primary mechanism new mechanism of action of action for low affinity for receptors and antagonist at alpha system beta nicotinic receptors well established mechanism of action alpha adrenergic agonist autonomic nervous efficacy for withdrawal supported by preclinical work mild moderate high variability in response reduction of autonomically mediated symptoms side effect profile appears to be mor bradycardia mild cardiac risk dosing adjusted for renal and kidney function necessary dose taper medication schedule bolus dosing minimal | MindMed
overall summary there remains a need to identify mechanistically informed withdrawal medications may leverage some benefits observed with in a manner established an pathway for approval has some weaknesses that may limit its adoption or impact a cocktail treatment approach would be preferable mor | MindMed
key milestones study initiation | MindMed
significant unmet need for use disorder treatments | MindMed
novel mechanism to address a critical gap in treatment | MindMed
strong preclinical activity on key translational outcomes | MindMed
strong preclinical activity on key translational outcomes | MindMed
strong preclinical activity on key translational outcomes | MindMed
phase study results key phase study results support progression of into planned upcoming phase clinical program well tolerated up to per day in single ascending dose sad and per day in the multiple ascending dose mad linear maintained across the tested doses and frequencies clinical effects align with potent engagement regimen aligns with preclinical evidence offers potential to be a more effective regimen in withdrawal | MindMed
phase sad mad dosing cohorts | MindMed
phase sad mad adverse event tables a | MindMed
phase sad mad adverse event summaries | MindMed
phase sad curve | MindMed
phase mad comparison curve | MindMed
phase a supervised withdrawal in use disorder | MindMed
a | MindMed
See More
MindMed
Results Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Preclinical
Recent decks by MindMed
Investor Presentation
January 2025
Investor Presentation
December 2024
Investor Presentation
November 2024
Results
November 2023
See all presentations by MindMed (10 decks)
Related decks
Fusion Pharmaceuticals
Investor Presentation
January 2024
Tonix Pharmaceuticals
Investor Presentation
October 2022
AstraZeneca
Investor Conference
April 2023
AbCellera
Results
August 2021
Nuvalent
Investor Presentation
August 2023
Nuvalent
Investor Presentation
May 2023
Nuvalent
Investor Presentation
November 2023
Nuvalent
IPO
July 2021
Recent decks by MindMed
See all presentations (10 decks)
Investor Presentation
January 2025
Investor Presentation
December 2024
Investor Presentation
November 2024
Results
November 2023
Fusion Pharmaceuticals
Investor Presentation
January 2024
Tonix Pharmaceuticals
Investor Presentation
October 2022
AstraZeneca
Investor Conference
April 2023
AbCellera
Results
August 2021
Nuvalent
Investor Presentation
August 2023
Nuvalent
Investor Presentation
May 2023
Nuvalent
Investor Presentation
November 2023
Nuvalent
IPO
July 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights